Compare AbCellera Biologics Inc (ABCL) vs BigBearai Holdings Inc (BBAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs BigBearai Holdings Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while BigBearai Holdings Inc trades at $3.31 (market cap $1.64B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | BBAI | |
|---|---|---|
Market Cap | $2.35B | $1.64B |
Sector | Health | Technology |
52-Week High | $8.12 | $8.91 |
52-Week Low | $2.78 | $3.05 |
Enterprise Value | $1.99B | $1.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BBAI trades at $3.58, up 1.42% today, but technical indicators signal a bearish trend with strong selling pressure. The company reported a net loss of $293.91 million in 2025, with negative profit margins and cash flow from operations. Recent news highlights expansion into AI-powered airport security and government contracts, though high SG&A expenses and persistent losses remain concerns. Analyst consensus is cautious, with 75% hold ratings.
The outlook is challenged by ongoing losses and rich valuation, but growth in AI contracts and backlog offers potential upside. Key risks include execution on profitability, competitive pressures, and reliance on government spending. Investors should weigh the high-risk, high-reward profile amid volatile market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →
